Volume 6, Issue 4: Pulmonary Exacerbations and the Microbiology of the CF Lung
e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 6, Issue 4)
Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.
After participating in this activity, the participant will demonstrate the ability to:
- Describe how the complexity of the cystic fibrosis airway microbiome affects the management of pulmonary exacerbations
- Summarize the limitations of in vitro antimicrobial susceptibility testing in guiding antibiotic therapy of CF exacerbations
- Explain the role that bacterial species not routinely reported in cultures of CF respiratory specimens may play in contributing to pulmonary exacerbation and lung disease progression
John J. LiPuma, MD
Professor of Pediatrics University of Michigan
Ann Arbor, Michigan
Dr. John LiPuma reports that he has served as a consultant for Raptor Pharma, Aradigm Corp, and CURx Pharma.
Dr. John LiPuma reports there will be no off-label or unapproved uses of any drugs except for brief mentions of early-trial antibiotic combinations.
- 1.00 ANCC
- 1.00 Attendance